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the role of autoantibodies in the patho-
genesis of pemphigus and pemphigoid
Generation of autoantibodies to target 
antigens on keratinocytes is believed 
to drive the pathogenesis of pemphigus 
and pemphigoid, but the details of 
the molecular mechanisms govern-
ing autoantigen production and the 
mechanisms of antibody action are 
still under intense scrutiny. Antibodies 
to desmoglein 3 (Dsg3) and Dsg1 are 
the primary antibodies described in 
pemphigus vulgaris (PV) patients. In a 
review of additional autoantibodies 
against non-Dsg targets, Aimee Payne 
(University of Pennsylvania) empha-
sized that autoantibodies in PV serum 
may be either causative or merely asso-
ciated. She explained that antibodies 
to pemphaxin, the type of annexin that 
binds acetylcholine, and antimitochon-
drial autoantibodies are necessary but 
not sufficient to cause PV in a passive 
transfer model of the disease. In vivo 
studies with other antireceptor antibod-
ies have not yet been performed. The 
desmocollin 3 antibody appeared to be 
both necessary and sufficient to cause 
acantholysis in culture and mouse skin.
Work presented by David Rafei 
(Philipps University, Marburg, Germany) 
further demonstrated the role of IgG 
autoantibodies to desmocollin 3 in 
atypical pemphigus. Mina Kalantari 
(University of California–Irvine) 
described multiplex protein array 
The third international meeting cospon-
sored by the International Pemphigus 
and Pemphigoid Foundation (IPPF) and 
the National Institute of Arthritis and 
Musculoskeletal and Skin Diseases 
was attended by approximately 130 
scientists and clinicians represent-
ing the international pemphigus and 
pemphigoid community.* The intent 
of this meeting, organized by Sergei 
Grando (University of California–
Irvine), Victoria Werth (University 
of Pennsylvania, Philadelphia), Luis 
Diaz (University of North Carolina at 
Chapel Hill), and the late Jean-Claude 
Bystryn (New York University), was 
to assemble an international group of 
researchers and clinicians involved 
in pemphigus and pemphigoid 
research and treatment. This report 
highlights the research presentations, 
group discussions, and recommenda-
tions for future work (see the meeting 
program at http://www.pemphigus.
o r g / f i l e s / 2 0 1 0 P P - M e e t i n g P r o -
gram.pdf and accompanying pre-
sentations at http://www.pemphigus.
o r g / i n d e x . p h p ? o p t i o n = c o m _
content&view=article&id=396). In 
add ition, an overview of barriers 
to international collaborations and 
multicenter trials was presented 
along with recommendations for the 
development of a consensus algo-
rithm for treatment of pemphigus and 
pemphigoid.
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technology that enabled the ident i-
fication of 16 novel antigens targeted 
by PV autoantibodies. These antigens 
were found to be involved in signal 
transduction and cell developmental 
regulation (CD37, CD84, and CD66c), 
activation (CD37 and CD33), growth 
(CD37, CD40, and CD54), and adhe-
sion and motility (CD2, CD31, CD36, 
CD66c, CD54, and CD84). She also 
demonstrated pemphigus IgG binding 
to the Fc fragment of human IgG that 
has previously been used in chimeric 
constructs of Dsg1 and Dsg3 antigens. 
These immunoglobulins were able to 
remove all disease-causing activity from 
pemphigus sera. Kristina Seiffert-Sinha 
(Michigan State University, East Lansing) 
characterized an autoantigen microarray 
that identified both Dsg and non-Dsg 
targets, including muscarinic acetylcho-
line receptors and thyroid peroxidase, 
involved in PV. Future studies will exam-
ine the pathophysiological relevance of 
these antigens.
John Stanley (University of Penn-
sylvania) described the genetic charac-
terization of pemphigus antibodies via 
phage display cloning. In elegant work, 
he isolated human mAbs from PV and 
pemphigus foliaceus patients to define 
the antibody repertoire. Both patho genic 
and nonpathogenic antibodies specific 
for Dsg3, Dsg1, or both were identi-
fied, indicating shared epitopes across 
pemphigus sera. These autoantibodies 
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shared similarities in the CDR3 region 
and consequently in the target epitopes, 
and these findings offered the possi-
bility of identifying peptides or small 
molecules for therapeutics. Giovanni 
Di Zenzo (IDI-IRCCS, Rome, Italy) 
identified human mAbs that bound 
anti-Dsg3 epitopes and were shared 
among multiple PV patients. Richard 
Groves (King’s College London, UK) 
described a Luminex-based serological 
assay with greater sensitivity than tradi-
tional ELISAs for the evaluation of Dsg1 
and Dsg3 antibody levels.
Fogo selvagem (FS), an endemic 
form of PV in Brazil, is characterized 
by autoantibodies to Dsg1 believed 
to result from chronic exposure to 
an unknown environmental antigen. 
Description of the diversity of the 
autoantibody response in FS by Luis A. 
Diaz revealed that IgG4 was specifical-
ly pathogenic. In addition, these IgG4 
anti-Dsg1 autoantibodies could be 
used as markers and predictors of FS. 
In particular, the absence of IgG4 anti-
Dsg1 antibodies in sera offered a 99.7% 
chance that the patient was disease 
free. To explore the disease etiology of 
FS in more depth, Ye Qian (University 
of North Carolina) studied V-region 
gene usage of the anti-Dsg1 autoanti-
bodies using hybridoma production. 
No apparent restriction of heavy-chain 
usage was observed in FS patient anti-
bodies, although several heavy and 
light chains were preferentially used for 
anti-Dsg1 antibody generation. In addi-
tion, the majority of the anti-Dsg1 anti-
body heavy chains were mutated, and 
these mutations were shared among 
independent anti-Dsg1 antibodies from 
FS and pre-FS patients, suggesting that 
the same or a similar antigen is respon-
sible for antibody selection.
K. Aftab Rashid (Center for Blistering 
Diseases, MERSI, Boston, MA) identi-
fied the α6 integrin subunit and the β4 
integrin subunit as target antigens in 
oral pemphigoid and ocular cicatricial 
pemphigoid, respectively. Together, these 
findings should facilitate the develop-
ment of specific ELISAs for clinical testing 
and research into disease pathogenesis.
removing pathogenic antibodies
Because pathogenic autoantibodies 
underlie the pathology of pemphigus 
and pemphigoid, removal of the 
offending molecules is a promising 
therapeutic strategy. Several approaches 
to achieving this goal have been imple-
mented clinically, including intravenous 
immunoglobulin (IVIg), plasmaphere-
sis, and rituximab. Annette Czernik 
(University of California, Irvine) pro-
vided an update on the mechanism of 
action of IVIg in pemphigus and pem-
phigoid. The results of a double-blind 
randomized controlled trial of a single 
cycle of IVIg administration revealed 
that this treatment improved disease 
severity by rapidly and selectively 
decreasing pathogenic autoantibodies 
in blood. In addition, a case–control 
study demonstrated that the administra-
tion of IVIg in combination with a cyto-
toxic agent was associated with a more 
rapid decline in circulating pathogenic 
antibodies, a more rapid steroid taper, 
and a more rapid decrease in disease 
severity. The success of this treatment 
regimen involves the suppression and 
maintenance of low levels of pathogen-
ic antibodies. Although the mechanism 
of action of IVIg is complex, evidence 
indicates that IVIg acts directly on anti-
body levels by increasing catabolism 
via saturation of the FcRn receptor and/
or inactivating pathogenic antibodies 
with anti-idiotypic antibodies and that 
IVIg also inhibits acantholysis directly 
at the level of keratinocytes via sup-
pression of apoptotic pathways.
In a review of immunoadsorption 
and plasmapheresis, Rüdiger Eming 
(Philipps University) provided evi-
dence for the successful use of immu-
noapheresis (IA) in combination with 
systemic immunosuppression for pem-
phigus treatment. Furthermore, clinical 
remission correlates with a decrease 
in anti-Dsg IgG levels. A randomized, 
prospective, multicenter, parallel group 
study is in progress in Germany to 
investigate whether adjuvant IA is supe-
rior to standard immunosuppressive 
therapy. Importantly, IA appears to be 
safe and well tolerated, with minimal 
side effects.
Grant Anhalt (Johns Hopkins 
University, Baltimore, MD) reported 
that semiyearly maintenance therapy 
is required for effective remission in 
some patients treated with rituximab, 
an anti-CD20 mAb that kills B cells. 
In his opinion, treatment with ritux-
imab appears to be the most effective 
treatment for pemphigus, although 
this drug has not been approved by 
the US Food and Drug Administration 
for this indication. Notably, although 
adverse events are potentially severe, 
these reactions are very rare, support-
ing the use of this drug in combina-
tion with steroids. Giuseppe Cianchini 
(IDI-IRCCS) reported that this drug was 
effective as maintenance therapy in the 
absence of corticosteroids and that this 
regimen can improve morbidity and 
mortality. Detlef Zillikens (University of 
Lübeck, Germany) presented data that 
support the use of IVIg and rituximab 
treatment of patients with bullous pem-
phigoid (BP) and mucous membrane 
pemphigus (MMP). Mary Tomayko (Yale 
University, New Haven, CT) proposed 
that rituximab-mediated B-cell deple-
tion breaks the positive feed-forward 
loop, thus inhibiting activation of auto-
reactive B and T cells.
molecular mechanisms of blistering
The underlying molecular mechanisms 
of blistering that involve autoanti bodies 
in subepidermal detachment in 
pemphigoid and intraepidermal detach-
ment in pemphigus were reviewed in 
detail. Kim Yancey (University of Texas 
Southwestern, Dallas) described the 
role of antibodies directed at BP anti-
gens 1 and 2 (BPAG1 and BPAG2) in 
subepidermal detachment in BP. IgG 
antibodies to the immunodominant 
epitope NC16A on the keratinocyte type 
VII transmembrane collagen BPAG2 
elicit complement activation, mast cell 
degranulation, neutrophil infiltration 
of the basement membrane, and sub-
sequent skin separation. Furthermore, 
phosphorylation of collagen type VII is 
important in the disease, presumably 
because of the recognition of phos-
phorylated epitopes by BP antibodies. 
Zhi Liu (University of North Carolina) 
reported the generation of humanized 
BP180NC16A mice, which develop 
subepidermal blistering following trans-
fer of BP IgG. Experiments in animal 
models showed that high doses of IVIg 
block BP in a dose-dependent fashion, 
which is supported by the following 
evidence: IVIg competes for FcRn bind-
ing, FcRn-deficient mice are resistant 
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to BP with a concomitant decrease in 
anti-BP180 antibodies, and high doses 
of the IgG Fc domain but not the Fab 
domain inhibit BP blister formation.
In additional work on the patho-
genesis of BP, John Zone (University 
of Utah, Salt Lake City) demonstrated 
that IgE antibodies generated by 
hybridomas to the LABD97 epitope, a 
collagen VII antigen distal to the main 
BP180 antigenic site, produced ery-
thema, induction, and basement mem-
brane zone blisters in human skin and 
that this process was associated with 
degranulation of mast cells and eosino-
phil infiltration, possibly indicating the 
release of various immune modulators 
in this system. Marian Dmochowski 
(University of Poznan, Poland) empha-
sized involvement of a neutrophil 
elastase and eosinophil major basic 
protein in BP lesions.
During discussion of the molecular 
mechanisms of acantholysis in pem-
phigus, Marcel Jonkman (University of 
Groningen, The Netherlands) described 
immunofluorescence and electron 
microscopic changes in pemphigus 
skin and demonstrated that an increase 
in the intercellular space precedes loss 
of desmosomes in early lesions. Jens 
Waschke (University of Würzburg, 
Germany) characterized acantholysis 
as an active signaling-dependent pro-
cess that involves loss of cell cohesion 
via disruption of the actin cytoskeleton 
in PV patients. Studies from this group 
also identified an endogenous adhe-
sion-promoting signaling pathway that 
involves cAMP and p38 mitogen-acti-
vated protein kinase (MAPK).
Carlo Pincelli (University of Modena 
and Reggio Emilia, Italy) reviewed Fas 
system involvement in the apoptotic 
mechanisms of acantholysis in pemphi-
gus, and Steve Marchenko (University 
of California, Irvine) identified the 
role of antimitochondrial antibodies 
in activation of the intrinsic pathway 
of pemphigus acantholysis. According 
to Nicola Cirillo (University of Bristol, 
UK), apoptosis-independent caspase 
activation is an early pathogenic event 
in PV. Sergei Grando described a novel 
mechanism of skin blistering in PV 
termed “apoptolysis.” This mechanism 
links apoptotic pathways to basal cell 
shrinkage and suprabasal acantholysis 
via a five-step process: (i) binding of 
autoantibodies to PV antigens; (ii) acti-
vation of EGFR, Src, mTOR, MAPK, 
and other signaling components down-
stream of ligated antigens and triggering 
of cell death enzymatic cascades; (iii) 
basal cell shrinkage due to the collapse 
and retraction of tonofilaments cleaved 
by executioner caspases and the disso-
ciation of interdesmosomal adhesion 
complexes following phosphorylation 
of adhesion molecules; (iv) cleavage of 
cellular proteins by activated cell death 
enzymes and the resultant cell collapse 
and tearing off of desmosomes; and 
(v) rounding up and death of acantho-
lytic cells. Importantly, acantholysis 
and apoptosis of keratinocytes in PV 
are mediated by the same set of cell 
death enzymes. This unifying concept 
links unrelated observations to events 
surrounding acantholysis, opens new 
avenues of investigation into the patho-
genesis of pemphigus, and creates pos-
sibilities for new treatment approaches 
that involve blockade of signaling path-
ways or enzymatic processes that lead 
to blistering.
Blocking signaling pathways as therapy
Because signaling cascades contribute 
to cell fate, blockade of these pathways 
may be beneficial for the treatment of 
pemphigus and pemphigoid. Detlef 
Zillikens presented data on treatment 
with biologics (proteins or derivatives 
designed to resemble or exploit sub-
stances that occur naturally in the body). 
In addition to IVIg and rituximab, tumor 
necrosis factor (TNF)-α inhibition has 
been found to successfully treat BP and 
MMP, although the overall effective-
ness of TNF-α inhibition is not entirely 
conclusive. IgE antibodies to BP180 
have also been implicated in BP; hence, 
Janet Fairley (University of Iowa, Iowa 
City) presented the results of a pilot 
study of omalizumab, a humanized 
mAb that binds the IgE-binding domain 
on the high-affinity IgE receptor FcRε1, 
for the treatment of a small number 
of BP patients. The levels of NC16A-
specific IgE, BP180 IgG, and BP230 
IgG remained elevated despite clinical 
improvement in the patients treated with 
this mAb. Additional controlled clinical 
trials will be required to demonstrate the 
use of biologics in pemphigoid.
In the studies of inhibitors of signal-
ing pathways in animal models of PV, 
Augustin España (University of Navarra, 
Spain) reported that downstream activa-
tion of HER isoforms that activate RAS/
MAPK, STATs, PLCγ, and PI3K/Akt may 
play a role in lesion formation. In addi-
tion, a role for activation of the receptor 
tyrosine kinase FAK, which is mediated 
by nNOS, Src, and mTOR, in acantho-
lysis and apoptosis was documented. 
David Rubenstein (University of North 
Carolina) described the targeting of 
signaling molecules in a clinical trial. 
Because p38/MAPK is one of the sig-
naling molecules involved in PV patho-
genesis, a multicenter, open-label trial 
of an orally administered p38MAPK 
inhibitor KC706 was conducted with 
15 PV patients. Half the patients expe-
rienced a partial response to treatment; 
the remaining patients either failed 
to improve or experienced worsened 
disease. Although this signaling inhibi-
tor was not effective for treating PV, 
P38MAPK remains a viable target for 
therapy but requires a specific inhibitor 
that lacks off-target effects. In addition, 
other signaling targets, such as epider-
mal growth factor receptor, identified by 
Yoram Milner (The Hebrew University, 
Jerusalem, Israel) and Meryem Bektas 
(University of North Carolina), may be 
useful for therapeutic approaches alone 
or in combination with other targets.
regulation of antibody production  
and inflammation
Despite the identification of auto-
antibodies and the target antigens 
in pemphigus and pemphigoid, the 
central role of T cells and cytokines 
in the pathogenesis of these diseases 
invites further study. T cells are clearly 
involved in autoimmunity and may be 
important regulators in autoantibody-
mediated disease. Robert Eisenberg 
(University of Pennsylvania) described 
the ongoing B cell–T cell dialog that 
involves interactions at the cell sur-
face that in turn result in intracellular 
signaling in both cell types to alter 
gene expression patterns. Masayuki 
Amagai (Keio University School of 
Medicine, Tokyo, Japan) presented 
data describing the regulation of 
pathogenic autoantibody production 
in pemphigus. This group generated 
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Dsg3-specific T-cell receptor transgenic 
mice in order to analyze central and 
peripheral tolerance to Dsg3 in T cells. 
The autoimmune regulator was found 
to play an important role in thymic 
Dsg3 expression as well as in T-cell 
tolerance to Dsg3, offering an avenue 
for additional research into autoim-
mune disease etiology. Michael Hertl 
(Philipps University) then described 
T-cell control in pemphigus. Major 
histocompatibility complex class II 
molecules are involved in the autore-
active T-cell response to Dsg3 in pem-
phigus patients in the context of Dsg3 
epitope presentation by CD4+ T cells. 
Evidence of suppression of autoreac-
tive Dsg3-specific Th2 cells in patients 
with depleted B cells following ritux-
imab treatment and the link between 
disease relapse and the return of auto-
reactive T and B cells corroborate 
a role for the interaction between T 
cells and B cells in the pathogenesis of 
pemphigus. In addition, Edmond Yunis 
(Harvard Medical School, Boston, MA) 
demonstrated a role for natural killer 
cells in the pathogenesis of PV.
Anticytokine therapy
To unravel disease complexity in pem-
phigus, Animesh Sinha (Michigan State 
University) employed immunoprofiling 
via a systems approach that layers bio-
logical complexity onto clinical com-
plexity. Cytokines have been implicated 
as targets for novel therapeutic strategies 
for autoimmune skin blistering diseases. 
Ralf Ludwig (University of Lübeck) pro-
vided evidence for increased levels of 
the important cytokines TNF-α, IL-1β, 
IL-2, IL-6, and IL-10 in the skin and/or 
serum of pemphigus and pemphi goid 
patients. Levels of IL-1β, IL-8, IL-5, and 
TNF-α appear to correlate with disease 
activity. In addition, clinical reports 
indicate successful use of TNF-α 
inhibitors in at least nine patients with 
MMP, although no controlled trials have 
been published. Although the evidence 
is promising for the therapeutic target-
ing of these molecules, more work at 
the bench is required before these 
therapies can be moved to the bedside. 
Several groups have begun to explore 
the utility of cytokine-blocking biolog-
ics as treatment strategies. Evidence for 
a role for TNF-α in PV includes a lack 
of blistering following passive transfer 
of PV IgG to TNF-α-deficient mice, 
the abundant TNF-α mRNA in PV skin 
lesions, the correlation between serum 
TNF-α levels and disease activity and 
antibody titers, and the observed ben-
efits of infliximab and etanercept for 
refractory PV. In light of this accumu-
lating evidence, Russell Hall (Duke 
University, Durham, NC) conducted 
a phase II double-blind placebo-con-
trolled trial of infliximab in PV patients 
to determine the safety and potential 
efficacy. The results are being analyzed 
and will be available in the near future.
moving forward: defining clinical  
disease markers, overcoming barriers  
to international collaborations, and 
developing a treatment algorithm
One of the overriding goals of this meet-
ing of the pemphigus and pemphigoid 
experts was to develop a consensus on 
terminology and criteria for disease 
severity and outcomes that can be used 
in international collaborative studies on 
disease etiology and treatment. Victoria 
Werth discussed efforts to define clinical 
disease outcome definitions and activity 
measures for pemphigus and pemphi-
goid. Definitions for pemphigus were 
developed by an inter national commit-
tee established in 2005 as an outgrowth 
of the last National Institutes of Health 
pemphigus meeting. Definitions related 
to outcomes in pemphigoid are being 
finalized with the goal that clinical 
researchers will utilize these definitions 
in trial design, analysis, and publication 
to facilitate comparison and analysis of 
studies from different countries. In addi-
tion to these definitions, a score that can 
be validated for use in comparison of 
these trials is needed. The international 
committee met several times during the 
meeting to develop a consensus on the 
design of the bullous pemphigoid disease 
activity index. Once the index has been 
finalized, additional valid ation stud-
ies will be necessary to ensure optimal 
design of this disease activity measure.
David Sirois (New York University), 
the president of the IPPF, emphasized 
its role in advocacy, support, encour-
agement, education, and networking 
for both patients and researchers. The 
launch in May 2010 of the IPPF National 
Disease Registry, which encompasses a 
web-based, patient-reported database 
that includes clinical phenotype, lesion 
activity, treatment and outcomes, demo-
graphics, and a future module to collect 
biological specimens, will spearhead 
the efforts of the research community 
to define the molecular etiology of 
pemphigus and pemphigoid and will 
enable assessment of treatment options 
in a large database of up to thousands 
of patients with these rare diseases. 
Clinicians are encouraged to direct 
patients to the registry to contribute to 
the systematic collection of disease 
information that will facilitate discovery 
(http://www.pemphigus.org).
Multicenter trials for treatment of 
blistering diseases are imperative, in 
part because of the small numbers of 
patients with these diseases. In the 
United States, four such multicenter 
trials of PV treatment (dapsone, Dsg3 
synthetic peptide PI-0824, p38MAPK 
inhibitor, and infliximab) have been 
conducted. Victoria Werth described 
barriers to these studies, including 
low numbers of available patients, 
minimal funding for prospective ran-
domized trials, and the limited market 
for new agents. A lack of recognition 
of the importance of these trials by 
industry and academia, high start-up 
costs despite small study sample sizes, 
extended timelines for trial completion, 
and stringent regulatory requirements 
also obstruct these types of multicenter 
studies. Furthermore, because the field 
is near its infancy in clinical trials, little 
high-quality evidence is available to 
support particular treatments.
As the research community is enter-
ing a new era with the recent develop-
ments of outcome definitions in 2008, 
disease-severity measures in 2009, and 
novel trial designs for the rarer diseases, 
the possibility of the establishment of 
research networks and international 
collaborations is emerging. Established 
research networks have the benefit of 
faster and less costly start-up; availability 
of centers, personnel, data systems, and 
forms; established cohorts; combined 
expertise; and recycled experience. 
Collaboration among centers is ulti-
mately the only way to make adequate 
and timely progress in accumulating 
evidence for the efficacy of treatment 
for these rare blistering diseases.
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Providing the European perspective, 
Michael Hertl described the establish-
ment of the European Clinical Research 
Infrastructures Network, which was 
created to integrate clinical research 
by connecting national networks of 
academic clinical research centers in 
13 countries. The goal of this organ-
ization is to facilitate compliance 
with the European Union´s Clinical 
Trials Directive. The benefits of this 
initiative include case report forms, 
data management, trial support, use of 
electronic data capture, scientific inter-
action, and increased access to patients 
for individual studies. Although this 
initiative is commendable, difficulties 
in quality management of data and dif-
ferences between ethics committees in 
member countries present roadblocks 
to complete harmonization. As an 
example of a successful multicenter trial 
in Japan, Masayuki Amagai described a 
randomized double-blind trial of IVIg 
for pemphigus that involved 24 medi-
cal institutes and was supported by a 
domestic pharmaceutical industry.
Overall, these perspectives offered 
insight into the difficulties that must be 
overcome to fund and conduct the nec-
essary multicenter trials for pemphigus 
and pemphigoid treatment. Consensus 
definitions and outcomes are appealing 
to funding agencies, and studies of total 
cost versus benefits will be important.
Grant Anhalt indicated that several 
barriers must be addressed in order to 
establish guidelines for treatment. First, 
the term “successful treatment” must be 
defined in terms of remission and remit-
tive results. Second, in the United States, 
insurance restrictions often influence 
drug preference and availability. These 
restrictions may stem, in part, from the 
lack of high-quality clinical trials that 
form the basis of therapeutic decision 
making. As indicated above, very few 
double-blind randomized controlled tri-
als have been conducted for the various 
therapies, and the power of many pem-
phigus studies is limited by small sample 
sizes. Further studies on the pathophysi-
ology of the disease and the mechanism 
of action of drugs will promote only 
drugs for which there is a strong rationale 
for use in treatment of pemphigus and 
pemphigoid. Finally, a mechanism for 
sharing treatment data, such as the reg-
istry implemented by the IPPF, will allow 
for the necessary numbers of analyzed 
patients and facilitate the development 
of an algorithm for treatment.
Sharing a European perspective, 
Luca Boradorri (University of Bern, 
Switzerland) also described hurdles 
to this treatment algorithm. A lack of 
standards in dermatology across Europe 
contributes to this difficulty. In addition, 
clinical management of pemphigus 
may be handled by dermatologists, 
general practitioners, or even ear, nose, 
and throat physicians, depending on the 
location in Europe. A precise diagnosis is 
critical for efficacious treatment, and the 
availability of diagnostic assays may be 
difficult in some settings. Furthermore, 
the multiple health systems across Europe 
provide varying access to derma tologists 
and have different reimbursement poli-
cies, which affect treatment choices. 
As a result, treatment strategies are 
not uniform, based on studies in 
France, Switzerland, Germany, and the 
Netherlands. Consensus conferences 
focused on IA, rituximab therapy, and 
IVIg treatment were held in Germany 
in 2007, 2008, and 2009, respectively. 
Thus, individual countries in Europe are 
making an effort to develop consensus 
treatment guidelines.
According to Masayuki Amagai, the 
unique circumstances of the universal 
Japanese health-care system yield both 
advantages and disadvantages for the 
development of a treatment algorithm 
for pemphigus. Universal health care 
is available to all citizens; however, 
government approval of new drugs is dif-
ficult to obtain, and therefore the poten-
tially efficacious drugs mycophenolate 
mofetil and rituximab are not available 
for treatment of pemphigus patients in 
Japan. The Japanese Dermatological 
Association recently published guide-
lines for the management of pemphi-
gus. From a Middle Eastern perspective, 
Cheyda Chams Davatchi (Tehran 
University for Medical Sciences, Iran) 
indicated that, although corticosteroids 
remain the mainstay of therapy, different 
doses are used throughout the Middle 
East, and adjuvant therapy is employed 
for different disease states, with different 
regimens, and in different combin-
ations in Iran, India, Kuwait, Turkey, and 
Bangladesh.
The fact that corticosteroid use is a 
common denominator in treatment strat-
egies across the globe offers a starting 
point for an international consensus. 
Development of an internationally 
agreed-upon algorithm for the treatment 
of pemphigus and pemphigoid will be 
quite an undertaking, albeit a critical next 
step for facilitating the necessary inter-
national collaborations in research and 
treatment evaluation. Special attention 
should be paid to unique disease situa-
tions when developing these guidelines 
and to particular patient characteristics, 
including clinical phenotype, the extent 
of cutaneous and/or mucosal lesions, 
and a patient’s age and associated 
medical conditions.
Conclusions
The attendees and organizers hope that 
this meeting will have a dramatic impact 
on the development of coordinated 
efforts to drive the research and treatment 
of immunobullous dermatoses. Future 
work to address immunomodulation in 
pemphigus and pemphigoid (autoanti-
gens, pathogenic antibodies, T cell–B 
cell interactions, and immune regulation) 
and investigation of therapeutic possibili-
ties unearthed by these studies is critical. 
The experimental evidence presented, 
in combination with the universal call to 
work together as an international com-
munity, has set the stage in the coming 
months for the generation of consensus 
terminology and criteria for the descrip-
tion of disease severity and response to 
treatment. The development of a patient 
registry by the IPPF promises increased 
access to patients and treatment out-
comes, and this access will ultimately 
propel the field toward an international 
algorithm for treatment.
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